Literature DB >> 6180091

Monitoring of interferon therapy by assay of (2'--5') oligo-isoadenylate synthetase in human peripheral white blood cells.

A Schattner, G Merlin, D Wallach, H Rosenberg, T Bino, T Hahn, S Levin, M Revel.   

Abstract

With the increasing number of patients undergoing experimental interferon therapy, there is a need for a method for monitoring how the patients respond to the drug. Interferon induces in cells exposed to it the accumulation of several enzymes, among them the (2'-5') oligo-A synthetase. A simple method previously developed was used to measure this enzyme in extracts of a small number of peripheral white blood cells. In 60 healthy volunteers, the enzyme level in the mononuclear cell fraction was found to be relatively high and constant. Daily intramuscular injections of 1--2 x 10(6) units leukocyte type interferon (IFN-alpha) increased the enzyme level 7--8 fold in mononuclear cells and in granulocytes. The enzyme stayed high until IFN injections were stopped. Patients with defective response to IFN were identified. We propose that this method be used for continuous monitoring of the patient's response whenever interferon therapy is undertaken.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6180091     DOI: 10.1089/jir.1981.1.587

Source DB:  PubMed          Journal:  J Interferon Res        ISSN: 0197-8357


  18 in total

Review 1.  Biological response modifiers in the management of patients with breast cancer.

Authors:  D L Longo; L C Hartmann
Journal:  Breast Cancer Res Treat       Date:  1990-09       Impact factor: 4.872

2.  Absence of the 40-kDa form of (2'-5')oligoadenylate synthetase and its corresponding mRNA from skin fibroblasts derived from Alzheimer disease patients.

Authors:  K K Khanna; S J An; J M Wu; S Landolfo; A G Hovanessian
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-01       Impact factor: 11.205

3.  2'-5' oligo-A-synthetase activity in bovine peripheral blood leukocytes and alveolar macrophages exposed to recombinant interferons and tumor necrosis factor-alpha.

Authors:  H B Ohmann; M Campos; P J Griebel; L A Babiuk
Journal:  Can J Vet Res       Date:  1989-04       Impact factor: 1.310

4.  Serum 2'-5'oligoadenylate synthetase as a monitoring marker of anti-viral effect during interferon therapy for chronic type B hepatitis.

Authors:  Y Karino; T Sugawara; A Saga; J Yoshida; T Matsushima; T Miyazaki; J Toyota; Y Okuuchi
Journal:  Gastroenterol Jpn       Date:  1989-04

5.  Activation of 2',5'-oligoadenylate synthetase and B-2 microglobulin in cancer patients treated with partially pure gamma interferon: dependence of biological effect on administration route.

Authors:  M G Rosenblum; A Riso; J U Gutterman
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

6.  Influence of alpha-interferon therapy on blood lymphoid cells. Studies on antibody production, mixed lymphocyte culture response, mitogen responsiveness and 2'-5'oligoadenylate synthetase activity.

Authors:  S Einhorn; P Ling; N Einhorn; H Strander; J Wasserman
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

7.  Effect of interferon on Vero cells persistently infected with Sendai virus compared to Vero cells persistently infected with SSPE virus.

Authors:  M Crespi; M N Chiu; J K Struthers; B D Schoub; S F Lyons
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

8.  Molecular cloning and sequence of partial cDNA for interferon-induced (2'-5')oligo(A) synthetase mRNA from human cells.

Authors:  G Merlin; J Chebath; P Benech; R Metz; M Revel
Journal:  Proc Natl Acad Sci U S A       Date:  1983-08       Impact factor: 11.205

9.  Detection of elevated levels of 2-5A synthetase in serum from children with various infectious diseases.

Authors:  H Sugino; I Mitani; M Koike; T Kodama; J Sokawa; H Sawai; K Ishibashi; M Itoh; S Watanabe; Y Sokawa
Journal:  J Clin Microbiol       Date:  1986-09       Impact factor: 5.948

10.  (2'-5') Oligo A synthetase in human polymorphonuclear cells increased activity in interferon treatment and in viral infections.

Authors:  A Schattner; G Merlin; V Bregman; T Hahn; S Levin; M Revel; D Wallach
Journal:  Clin Exp Immunol       Date:  1984-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.